Jincheng Pharm(SZ:300233) Chang Jiang Shang Bao·2025-12-14 23:51Core Viewpoint - Zhao Yeqing, the actual controller of Jincheng Pharmaceutical, has been penalized for stock manipulation, leading to his resignation as chairman and director of the company [1][5]. Group 1: Stock Manipulation Case - From August 18, 2017, to February 10, 2020, Zhao Yeqing, Wang Zhen, and Liu Feng collectively manipulated Jincheng Pharmaceutical's stock, with Zhao being the decision-maker [2][4]. - During the manipulation period of 595 trading days, the account group participated in trading for 502 days, buying 119 million shares for a total of 2.134 billion yuan and selling 107 million shares for 1.87 billion yuan, resulting in an actual loss of 7.392 million yuan [2][3]. - The regulatory authority imposed a total fine of 3 million yuan on the three individuals, with Zhao Yeqing responsible for 1.5 million yuan, and he received a four-year market ban [4][5]. Group 2: Company Performance and Developments - Jincheng Pharmaceutical, founded in 2004, has evolved into a company with five strategic business areas, including pharmaceutical chemicals and synthetic biology [8]. - The company has experienced fluctuating performance, with revenues of 3.538 billion yuan and 3.373 billion yuan in 2023 and 2024, respectively, and a significant decline in net profit by 79.1% in the first three quarters of 2025 [9]. - A collaboration project with Giskit Pharma for a drug related to female infertility was terminated due to lack of progress and failure to reach a formal agreement [10][11].